Filing Flows › Beta Bionics (BBNX) › Q2 2025
Beta Bionics (BBNX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
Beta Bionics (BBNX) reported revenue of $23.2M for the second quarter 2025 (Q2 2025), +54% from a year earlier and +32% from the quarter before. Operating margin was -85.5%, net loss $16.9M (72.6% of revenue).
Beta Bionics, Q2 2025: revenue $23.2M (+54% year over year), operating margin -85.5%, net loss $16.9M, operating cash flow −$13.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.2M | +32% | +54% |
| Operating profit | −$19.9M | — | — |
| Net earnings | −$16.9M | — | — |
| Operating cash flow | −$13.6M | — | — |
What changed
Revenue was $23.2M in Q2 2025, up 54% year over year and up 32% from the previous quarter.
Gross margin was 53.8%, up 0.1 points from a year earlier. Operating costs exceeded revenue by $19.9M, an operating margin of -85.5%. Operating expenses grew 63% against revenue growth of 54%. The fastest-growing cost line was Sales & marketing (+74%). The quarter ended with a net loss of $16.9M, narrower than the previous quarter's $28.7M loss.
Operating cash flow was −$13.6M. Non-cash charges added back $347K of depreciation and $4.8M of share-based compensation. Working capital and other items used $1.9M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$15.4M.
Questions
What was Beta Bionics' revenue in the second quarter 2025?
Beta Bionics (BBNX) reported revenue of $23.2M for the second quarter 2025 (Q2 2025), +54% from a year earlier and +32% from the quarter before.
Was Beta Bionics profitable in the second quarter 2025?
Operating loss was $19.9M (-85.5% of revenue) and net loss $16.9M.
Source: Beta Bionics 10-Q on SEC EDGAR.